Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 49

Results For "EMA"

3503 News Found

Japan okays new long-acting eye drug
News | March 24, 2026

Japan okays new long-acting eye drug

It promises fewer injections for vision loss patients


Bayer wins world-first nod in Japan for low-dose MRI contrast agent
News | March 24, 2026

Bayer wins world-first nod in Japan for low-dose MRI contrast agent

Call it a major breakthrough for diagnostic imaging


LGM Pharma commits $15M to US facilities in major CDMO expansion
News | March 23, 2026

LGM Pharma commits $15M to US facilities in major CDMO expansion

This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing


Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy
News | March 23, 2026

Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy

The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety


TRIANA Biomedicines doses first patient in groundbreaking ALK+ lung cancer trial
News | March 23, 2026

TRIANA Biomedicines doses first patient in groundbreaking ALK+ lung cancer trial

The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611


Sakura Finetek and Hamamatsu forge alliance to transform digital pathology workflow
Medical Device | March 21, 2026

Sakura Finetek and Hamamatsu forge alliance to transform digital pathology workflow

Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process


Iberia Pharmaceuticals scores big with KeyCi launch, signals shift towards science-backed skincare
News | March 21, 2026

Iberia Pharmaceuticals scores big with KeyCi launch, signals shift towards science-backed skincare

KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval


Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer
Clinical Trials | March 21, 2026

Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer

The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival